急诊科性传播感染分子即时检测的成本与运营影响
该研究基于前后实施研究数据,采用成本表决策分析,比较大型城市学术急诊科(Johns Hopkins Hospital)女性疑似性传播感染患者使用集中实验室检测与分子即时检测(沙眼衣原体、淋病、滴虫)的医院和社会成本。结果显示,1000名女性中即时检测直接成本较集中实验室检测高16502美元,该差额未被随访成本或社会成本抵消。从医院角度,成本可能通过最大化急诊检查室利用率带来的边际收益抵消。阈值分析显示,检查室时间无需完全占用,边际收益也无需等于全额收入即可实现净收入增益。结论认为即时检测在当前定价下增加社会成本、减少医院收入,但急诊科和医院若候诊时间长,可能通过改善患者流通增加净收入。
要点
- 1000名女性中,分子即时检测直接成本较集中实验室检测高16502美元,该差额未被随访或社会成本抵消。
- 从医院角度,成本可能通过最大化急诊检查室利用率带来的边际收益抵消。
- 阈值分析显示,检查室时间无需完全占用,边际收益也无需等于全额收入即可实现净收入增益。
- 结论认为在当前定价和报销不变下,即时检测增加社会成本并减少医院收入;候诊时间长时医院可能通过改善患者流通增加净收入。
适用人群与场景
- 急诊科女性患者,疑似性传播感染(沙眼衣原体、淋病、滴虫)。
- 场景:大型城市学术急诊科(Johns Hopkins Hospital)。
研究设计与关键结果
- 研究设计:基于前后实施研究数据的成本表决策分析,从医院和社会角度、12个月时间范围进行分析。
- 干预与对照:分子即时检测 vs 集中实验室检测(核酸扩增检测/湿片)。
- 主要结果:1000名女性中,即时检测直接成本较集中实验室检测高16502美元。
- 该差额未被治疗不足的随访成本或治疗不足/过度的社会成本抵消。
- 从医院角度,成本可能通过最大化急诊检查室利用率带来的边际收益抵消。
- 阈值分析显示,检查室时间无需完全占用、边际收益也无需等于全额收入即可实现净收入增益。
- 结论:即时检测在当前定价和报销不变下增加社会成本并减少医院收入;若急诊候诊时间长,急诊科和医院可能通过改善患者流通增加净收入。
证据类型、等级与局限
- 证据类型:基于前后实施研究数据的成本表决策分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为:在当前定价和报销不变下,分子即时检测增加社会成本并减少医院收入;但若急诊候诊时间长,急诊科和医院可能通过改善患者流通增加净收入。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Female patients presenting to the emergency department (ED) with suspected sexually transmitted infections (STIs) have historically been evaluated using centralized laboratory testing (CLT), with results unavailable during the visit. Point-of-care (POC) tests enable real-time diagnosis but have higher direct costs than CLT.
OBJECTIVE: To compare hospital and societal costs of CLT and POC STI testing (chlamydia, gonorrhea, trichomonas) among female ED patients with suspected infection, and to assess effects on underdiagnosis, overtreatment, undertreatment, and ED recidivism.
DESIGN: Decision analysis through cost tables using data from a pre-post implementation study.
SETTING: Large urban academic ED (Johns Hopkins Hospital).
INTERVENTIONS: CLT (nucleic acid amplification test [NAAT]/wet preparation) versus molecular POC STI testing.
MEASUREMENTS: Direct testing costs, follow-up costs for informing patients after discharge, costs of overtreatment/undertreatment, and ED return visits within 30 days. Analyses were conducted from hospital and societal perspectives over 12-month horizon.
RESULTS: Direct POC testing costs for 1000 women exceeded CLT by $16,502. This difference was not offset by lower follow-up costs for undertreatment or by societal costs of under- or overtreatment. From the hospital perspective, costs may be offset by increased margins from maximizing ED Examination room utilization. Threshold analysis shows room time need not be fully occupied, nor margins equal full revenue, to achieve net revenue gain.
CONCLUSIONS: POC testing for STIs, given current pricing and unchanged reimbursement, increases societal costs and reduces hospital revenue versus CLT. However, EDs and hospitals may increase net revenue, by improved patient throughput thereby generating revenue if ED wait times are long.
参考来源
- Am J Emerg Med:Cost and operational impact of a molecular point-of-care test for sexually transmitted infections in the emergency department
- Paul-Ledesma A, Dashler G, Hsieh YH, et al. Cost and operational impact of a molecular point-of-care test for sexually transmitted infections in the emergency department. Am J Emerg Med. 2026. PMID: 43002826. doi:10.1016/j.ajem.2026.10.038
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。